These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 30507409)

  • 1. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial.
    Delany-Moretlwe S; Lombard C; Baron D; Bekker LG; Nkala B; Ahmed K; Sebe M; Brumskine W; Nchabeleng M; Palanee-Philips T; Ntshangase J; Sibiya S; Smith E; Panchia R; Myer L; Schwartz JL; Marzinke M; Morris L; Brown ER; Doncel GF; Gray G; Rees H
    Lancet Infect Dis; 2018 Nov; 18(11):1241-1250. PubMed ID: 30507409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial.
    Skoler-Karpoff S; Ramjee G; Ahmed K; Altini L; Plagianos MG; Friedland B; Govender S; De Kock A; Cassim N; Palanee T; Dozier G; Maguire R; Lahteenmaki P
    Lancet; 2008 Dec; 372(9654):1977-87. PubMed ID: 19059048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
    Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial.
    McCormack S; Ramjee G; Kamali A; Rees H; Crook AM; Gafos M; Jentsch U; Pool R; Chisembele M; Kapiga S; Mutemwa R; Vallely A; Palanee T; Sookrajh Y; Lacey CJ; Darbyshire J; Grosskurth H; Profy A; Nunn A; Hayes R; Weber J
    Lancet; 2010 Oct; 376(9749):1329-37. PubMed ID: 20851460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
    Abdool Karim Q; Abdool Karim SS; Frohlich JA; Grobler AC; Baxter C; Mansoor LE; Kharsany AB; Sibeko S; Mlisana KP; Omar Z; Gengiah TN; Maarschalk S; Arulappan N; Mlotshwa M; Morris L; Taylor D;
    Science; 2010 Sep; 329(5996):1168-74. PubMed ID: 20643915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial.
    Gray GE; Mngadi K; Lavreys L; Nijs S; Gilbert PB; Hural J; Hyrien O; Juraska M; Luedtke A; Mann P; McElrath MJ; Odhiambo JA; Stieh DJ; van Duijn J; Takalani AN; Willems W; Tapley A; Tomaras GD; Van Hoof J; Schuitemaker H; Swann E; Barouch DH; Kublin JG; Corey L; Pau MG; Buchbinder S; Tomaka F;
    Lancet Infect Dis; 2024 Jul; ():. PubMed ID: 39038477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FAME-04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir.
    Bunge KE; Dezzutti CS; Hendrix CW; Marzinke MA; Spiegel HML; Moncla BJ; Schwartz JL; Meyn LA; Richardson-Harman N; Rohan LC; Hillier SL
    J Int AIDS Soc; 2018 Aug; 21(8):e25156. PubMed ID: 30101439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
    Baeten JM; Donnell D; Mugo NR; Ndase P; Thomas KK; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kidoguchi L; Coombs RW; Hendrix C; Marzinke MA; Frenkel L; Haberer JE; Bangsberg D; Celum C;
    Lancet Infect Dis; 2014 Nov; 14(11):1055-1064. PubMed ID: 25300863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ogbuagu O; Ruane PJ; Podzamczer D; Salazar LC; Henry K; Asmuth DM; Wohl D; Gilson R; Shao Y; Ebrahimi R; Cox S; Kintu A; Carter C; Das M; Baeten JM; Brainard DM; Whitlock G; Brunetta JM; Kronborg G; Spinner CD;
    Lancet HIV; 2021 Jul; 8(7):e397-e407. PubMed ID: 34197772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.
    Delany-Moretlwe S; Hughes JP; Bock P; Ouma SG; Hunidzarira P; Kalonji D; Kayange N; Makhema J; Mandima P; Mathew C; Spooner E; Mpendo J; Mukwekwerere P; Mgodi N; Ntege PN; Nair G; Nakabiito C; Nuwagaba-Biribonwoha H; Panchia R; Singh N; Siziba B; Farrior J; Rose S; Anderson PL; Eshleman SH; Marzinke MA; Hendrix CW; Beigel-Orme S; Hosek S; Tolley E; Sista N; Adeyeye A; Rooney JF; Rinehart A; Spreen WR; Smith K; Hanscom B; Cohen MS; Hosseinipour MC;
    Lancet; 2022 May; 399(10337):1779-1789. PubMed ID: 35378077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial.
    Sokal DC; Karim QA; Sibeko S; Yende-Zuma N; Mansoor LE; Baxter C; Grobler A; Frolich J; Kharsany AB; Miya N; Mlisana K; Maarshalk S; Karim SS
    Antivir Ther; 2013; 18(3):301-10. PubMed ID: 22914267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
    Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG
    Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
    Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
    Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
    Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM;
    Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial.
    ENCORE1 Study Group
    Lancet; 2014 Apr; 383(9927):1474-1482. PubMed ID: 24522178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Choopanya K; Martin M; Suntharasamai P; Sangkum U; Mock PA; Leethochawalit M; Chiamwongpaet S; Kitisin P; Natrujirote P; Kittimunkong S; Chuachoowong R; Gvetadze RJ; McNicholl JM; Paxton LA; Curlin ME; Hendrix CW; Vanichseni S;
    Lancet; 2013 Jun; 381(9883):2083-90. PubMed ID: 23769234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial.
    Keller MJ; Wood L; Billingsley JM; Ray LL; Goymer J; Sinclair S; McGinn AP; Marzinke MA; Frank B; Srinivasan S; Liu C; Atrio JM; Espinoza L; Mugo N; Spiegel HML; Anderson PL; Fredricks DN; Hendrix CW; Marrazzo J; Bosinger SE; Herold BC
    Lancet HIV; 2019 Aug; 6(8):e498-e508. PubMed ID: 31320290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical microbicides for preventing sexually transmitted infections.
    Obiero J; Ogongo P; Mwethera PG; Wiysonge CS
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD007961. PubMed ID: 33719075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
    Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.